Alzamend Neuro shares surged after dosing the first patient in its AL001 Phase II trial. This novel lithium formulation aims for improved brain delivery and fewer side effects. Last Chance: Access your full investing command center-trade ideas, screeners, expert insights for 60% off.

First of five Phase 2 trials for AL001 begins in healthy subjects with topline data expected by end of 2025. Preclinical data showed AL001 improved brain absorption with lower blood lithium levels compared to current treatments.

QMENTA's AI platform will streamline imaging analysis and ensure regulatory compliance during all trials. Alzamend to launch five Phase 2 trials of AL001, including PTSD and bipolar disorder, starting Q3 and Q4 of 2025.

After losing some value lately, a hammer chart pattern has been formed for Alzamend Neuro (ALZN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Alzamend's Phase 2 AL001 study for PTSD starts in Q4 2025 with Mass General Hospital as the contract research organization. AL001 improves brain lithium absorption while reducing systemic side effects, offering a safer alternative to current treatments.